6.4. role multimodal chemotherapy/radiotherapy management (regional) lymph nodes. 6.4.1. systemic therapy 6.4.1.1. neoadjuvant chemotherapy bulky inguinal ln enlargement indicates extensive lymphatic metastatic disease patients benefit surgery alone. neoadjuvant chemotherapy inguinal ln surgery allows early treatment systemic disease down-sizing inguinal ln metastases. responders, complete surgical treatment possible reasonable clinical outcome. cisplatin/5-fu (pf) chemotherapy achieved response rates 25–50% acceptable toxicity . period 30 years, five different nac regimens including pf used twenty patients, long-term survival 37% responders underwent radical ln surgery nac . eortc cancer study 30992, 26 patients locally-advanced metastatic disease received irinotecan cisplatin chemotherapy. although study meet primary endpoint (response rate), three cases pathologically complete remissions (pcrs) . hypothetical similarities penile scc head neck scc led evaluation penile cancer chemotherapy regimens efficacy head neck scc, including taxanes. phase ii trial evaluated treatment 4 cycles neoadjuvant paclitaxel, cisplatin, ifosfamide (tip) patients clinical n2 n3 ln metastases . objective response rate (orr) 50% reported 30 patients, including three pcrs. estimated median time progression (ttp) 8.1 months median os 17.1 months. long-term dfs observed 67% responding patients 7% non-responding patients. combination pf plus taxane used neoadjuvant adjuvant settings . phase ii trial docetaxel, cisplatin, 5-fu (tpf) reported objective response 38.5% 29 locally-advanced metastatic patients, although study meet primary endpoint, significant toxicity . prospective study testing neoadjuvant tpf 26 patients loco-regionally advanced penile cancer showed pathologic complete response one patient, 2-year pfs dss probability 12% 28%, respectively . treatment discontinued 23% patients toxicity. recent meta-analysis analysing 10 studies (n = 182 patients, mostly retrospective), pooled orr 53% (95% ci: 42–64), overall mortality 55% (95% ci: 40–70) . available evidence favours cisplatin- taxane-based combination (doublet triplet) preferred approach. overall, results support activity pre-operative chemotherapy patients clinically-involved regional lns penile scc. however, randomised studies lacking substantial concerns remain regarding selection patients best suited systemic therapy approach upfront. large retrospective study including 743 patients received lnd several international institutions suggested patients clinical n3 stage constituted cohort appreciable benefit nac use, compared lnd alone . bilateral inguinal ln involvement emerged strong negative predictor clinical outcome patients penile scc, together pelvic nodal involvement. summary, given poor outcome upfront surgery, nac potentially-suitable approach patients pelvic ln (cn3) metastases fixed inguinal ln involvement (cn3), bulky bilateral involvement (cn2). nonresponding patients, potential benefits surgery re-evaluated prognosis poor patients. see also section chemo-radiotherapy. 6.4.1.2. adjuvant chemotherapy known poor prognostic characteristics subset patients resected high-risk disease (such involved pelvic lns), indicating likely presence micrometastatic disease. data exists response rates metastatic disease possible benefit pre-operative chemotherapy unresectable locally advanced disease described above. extrapolation diseases, stands reason systemic therapy following resection (i.e., adjuvant therapy) may improve outcomes. retrospective multicentre analysis patients resected pathologically involved pelvic lns suggested potential benefit adjuvant chemotherapy . series, 84 patients analyzed. patients received chemotherapy relapsed disease excluded. compared receiving adjuvant chemotherapy, patients received adjuvant chemotherapy younger, lower stage, likely unilateral (rather bilateral) ln involvement, less likely receive adjuvant radiation. multivariable analysis, receipt adjuvant chemotherapy associated improved os (hr: 0.40, 95% ci: 0.19–0.87, p = 0.021). additional series also reported, including series 611 patients national cancer database reported abstract form . adjusting co-variates, difference survival receiving adjuvant chemotherapy. recent meta-analysis examined issue. systematic search, 7 studies identified examining use peri-operative chemotherapy, 4 examined adjuvant chemotherapy (n = 771) . difference survival receiving adjuvant chemotherapy vs. observation (hr: 0.95, 95%ci: 0.48–1.80). upon examination overall data, strong data supporting use adjuvant chemotherapy improve os following surgical resection primary tumour involved lns. however, given fact rfs relevant endpoint suboptimally studied subset patients high risk recurrence, panel recommends balanced discussion risks benefits adjuvant chemotherapy thought healthy candidates. previously stated neoadjuvant setting, benefit adjuvant chemotherapy expected highest population patients pathological n3 stage, particular patients pelvic nodal involvement . see also section 6.4.1.2 adjuvant radiation chemo-radiotherapy. 6.4.1.3. summary evidence guidelines neoadjuvant adjuvant chemotherapy summary evidenceleresults support activity nac patients clinically involved regional lns penile scc. however, randomised studies lacking, substantial concerns remain regarding selection patients best suited systemic therapy approach upfront.2bthe available evidence favours cisplatin- taxane-based combination (doublet triplet) preferred approach.2blimited data support use adjuvant chemotherapy improve os following surgical resection. however, could offered patients pn3 disease post-lnd nac received, upon careful consideration risks benefits patient.4 recommendationsstrength ratingoffer neoadjuvant chemotherapy using cisplatin- taxane-based combination chemotherapy-fit patients pelvic lymph node involvement extensive inguinal involvement (cn3), preference front surgery.weakoffer chemotherapy alternative approach upfront surgery selected patients bulky mobile inguinal nodes bilateral disease (cn2) candidates cisplatin taxane-based chemotherapy.weakhave balanced discussion risks benefits adjuvant chemotherapy high-risk patients surgically resected disease, particular pathological pelvic ln involvement (pn3). see also section post-operative radiotherapy.weak 6.4.2. radiotherapy 6.4.2.1. pre-operative radiation therapy role pre-operative chemo-radiotherapy investigated ongoing inpact trial . since surgical therapy enlarged lns paramount importance, unlikely pre-operative radiotherapy alone would provide sufficient benefit. patient otherwise unfit chemotherapy require treatment lns awaiting surgery, radiotherapy alone may considered using conventional daily fractionation 45–50gy. radiotherapy groins penile cancer conceptually requires inclusion pre-pubic fat order cover transit lymphatics . 6.4.2.2. post-operative radiation therapy adjuvant radiation therapy node-positive penile cancer remains controversial. since level 1 evidence support benefit radiation therapy terms disease recurrence survival, recommended prior guidelines . radiotherapy used institutions management regional lns penile scc, based evidence experience scc sites (such head/neck vulvar carcinomas) . jaipuria et al., reported following inguinal- pelvic lnd, patients > 2 positive lns negative pelvic nodes (n = 32) increased os adjuvant radiation therapy compared adjuvant chemotherapy (48 months vs. 14 months p < 0.0001) . although 68% patients ene, in-field failures. radiation dose higher commonly used circumstances, 54 gy ene 57–60 gy gross residual disease. lower radiation dose 50 gy, johnstone et al., reported high rate in-field failures (32/39) . dose, adjuvant radiation therapy (either groin: p = 0.016 inguinal-pelvic: p = 0.006) improved rfs patients without ene. ager et al., reporting experience pn3 disease (either ene pelvic ln+) two tertiary referral centres uk also found dose critically important . 121 146 patients received adjuvant radiotherapy. 5-year rfs 51%. twenty-six 55 recurrences in-field, risk in-field failure twice high lower doses < 50 gy. 92 patients positive pelvic ln 4 international centres, adjuvant radiation found prolong dss 6 months delay time recurrence . data collated table 6.3 reveal variable results conventional radiotherapy delivered adjuvant setting, potentially impacted hpv status presence/absence ene. also notable data fact traditional radiotherapy doses delivered microscopic disease may insufficient. recent genomic data analyses modelled higher radiation dose may necessary management penile cancer primary lesions nodal basins . table 6.3: adjuvant conventional radiotherapy node-positive penile cancer authornstageartadjctrtlrosstudy typejaipuria 2020 45anyt pn2-3pelvis pn-257vmat/imrt,45 gy basic,54 gy ene,57-60 macrono inf47 mo. rtvs. 14 mo. ctprospregistryjohnstone 2019 93anytpn3ene-ene+50/25 details↑os artp = 0.037or actp = 0.038↑dss artp = 0.044 centreswinters 2018 136pt1-3pn1-245 gy + boost 45%↑os art5 yr.64% vs. 53%ncdbtang2017 92n3 +pelvis4063% 50/25, 13% > 50 gy↑os art12.2 vs.8p=0.04↑dss14.4 vs.8p = 0.024 centresager2021 146pn3 (ene pelvis+)12145/20 54/252x↑lr < 5026 infos 44%rfs 5y 51%2 centres ukbandini 2021 507ilnd86hpv+40art↑os artp = 0.015also propensitymatched analysis11 centres adj = adjuvant; art = adjuvant radiotherapy; ct = chemotherapy; ene = extra-nodal extension; hpv = human papillomavirus; ilnd = inguinal lymph node dissection; mo = month; n = number patients; ncdb = national cancer database; os = overall survival; rfs = recurrence free survival; yr = year. hpv status could suitable selection factor patients benefit adjuvant radiotherapy ilnd (in analogy hpv-related cancers). bandini et al., reported 507 patients 11 centres, 86 hpv+. among patients receiving adjuvant radiotherapy, harbouring hpv-positive tumours appeared increased os relative hpv-negative patients. however, (prospective) studies needed validate findings . scc sites head neck cancer, hpv status may also predict increased responsiveness combined chemo-radiotherapy. yuan et al., reported improved loco-regional control (lrc) 83% 38% (p = 0.038) node-positive p16+ patients receiving chemo-radiotherapy following lnd . twenty-eight 51 patients ln+, 14 received chemo-radiotherapy, 7 hpv-positive. overall, regardless hpv status, 2-year lrc 54% receiving adjuvant chemo-radiotherapy vs. 13% (p = 0.006). choo et al., found similar efficacy adjuvant chemo-radiotherapy improved css one 2 years, even though patients selected adjuvant chemo-radiotherapy higher number positive lns (64% > 5 vs. 8%), pn3 disease (72% vs. 17%) ene (45% vs. 17%) . os unfavourable group receiving adjuvant chemo-radiotherapy favourable earlier-stage patients receiving chemo-radiotherapy. although plnd recommended patients high-risk groin pathology (n2–n3), practice jurisdictions. maibom et al., reported denmark use inguinal-pelvic chemo-radiotherapy 21 patients median follow-up 74 months . patients ene two-thirds bilateral groin disease, median os 84 months 57% 5-year survival. concept tested currently accruing inpact trial men high-risk groin pathology randomised chemo-radiotherapy plnd followed chemo-radiotherapy . 6.4.2.3. summary evidence guidelines pre- post-operative radiotherapy summary evidenceleadjuvant radiotherapy results increased os greater two inguinal ln-positive plnd-dissection negative.2badjuvant conventional radiotherapy doses often insufficient durable control. increased dss rfs penile cancer requires 54 gy ene 57–60 gy positive margins.3peri-operative chemo-radiotherapychemo-radiotherapy significantly improves loco-regional control radiotherapy alone scc originating anal canal head neck, whilst vulvar cancers improves os. evidence is, however, sparse penile cancer.1b recommendationsstrength ratingoffer adjuvant radiotherapy (with without chemo sensitisation) patients pn2/n3 disease, including received prior neoadjuvant chemotherapy.weakoffer definitive radiotherapy (with without chemo sensitisation) patients unwilling unable undergo surgery.weakoffer radiotherapy (with without chemo sensitisation) cn3 patients candidates multi-agent chemotherapy.weak